Altimmune Hit By Nasal COVID-19 Vaccine Failure, But Has A Plan B
Obesity Candidate Shows Promise
Executive Summary
Altimmune’s hopes of bringing a nasal COVID-19 vaccine to market have been dashed, but it is pivoting to novel peptide-based therapies.
You may also be interested in...
ImmunityBio Sees Booster Role For Under-The-Tongue COVID-19 Vaccine
In search of a differentiated approach, ImmunityBio’s candidate aims to boostT-cell immune responses via a subcutaneous and oral vaccine combination.
Canadian Biotech Progresses COVID-19 Nasal Spray, Claims Promise Against Variants
SaNOtize is to start Phase III trials for its nitric oxide nasal spray for COVID-19 and hopes to enlist volunteers from several countries, including India. The Canadian firm claims initial studies have demonstrated effectiveness across SARS-CoV-2 mutations, with plans afoot to validate it against the spreading Delta variant.
Novo Nordisk Hopes To Gradually Build US Access To Obesity Therapy
With US FDA approval of Wegovy for obesity, Novo Nordisk prices the weekly injectable at par with its other obesity brand Saxenda. Ramping up sales will require patient, clinician and payer education, the company says.